Close Menu

non-small cell lung cancer

This story originally ran on Dec. 13.
Biodesix last week presented results from a retrospective analysis of breast cancer patients using its serum proteomic Veristrat diagnostic.

Abbott said this week that it has expanded an existing immunotherapy companion diagnostic development agreement with GlaxoSmithKline to include a new target antigen.

Originally published Nov. 29.
Abbott and GlaxoSmithKline this week formally extended an existing drug/diagnostic codevelopment partnership in the cancer immunotherapy space, setting their sights on a new marker: the PRAME antigen.

A study published this month in the Journal of Thoracic Oncology supports the usefulness of Biodesix's VeriStrat lung cancer diagnostic in monitori

By Ben Butkus
This story has been updated from a version posted Oct. 25 to include comments from a GlaxoSmithKline spokesperson.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.